IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines

Cancer Investigation

Volumn 29, Issue 8, 2011, Pages 521-532

  Luk, Frederick ^a   Yu, Yan ^a   Walsh, William R ^a   Yang, Jia Lin ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chemoresistance; Doxorubicin; IGF1R targeted therapy; Osteosarcoma

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; DOXORUBICIN; SOMATOMEDIN C RECEPTOR; TYRPHOSTIN;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CHEMOSENSITIVITY; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; OSTEOSARCOMA; RECEPTOR, IGF TYPE 1; TYRPHOSTINS;

EID: 80052702630     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.606252     Document Type: Article

References (56)

1. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007;19:341-346. (Pubitemid 46883523)
2. de Saint Aubain Somerhausen N, Fletcher CDM. Sof-tissue sarcomas: an update. Eur J Surg Oncol 1999;25(2):215-220.
3. Anderson PM. Efectivness of radiotherapy for osetosarcoma that responds to chemotherapy. Mayo Clin Proc 2003;78:145-146. (Pubitemid 36158345)
4. Machak GN, Tkachev SI, Solovyev YN, Sinyukov PA, Ivanov SM, Kochergina NV, Ryjkov AD, Tepliakov VV, Bokhian BY, and Gle-bovskaya VV, Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma for extremities. Mayo Clin Proc 2003;78:147-155. (Pubitemid 36158346)
5. DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzen-rider JE, and Suit HD, Radiotherapy for local control of osteosar-coma. Int J Radiat Oncol 2005;61(2):492-498.
6. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, and Cui X, Te type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers Biosci 2008;13:3273-3287. (Pubitemid 351594682)
7. Hartog H, Wesseling J, Boezen HM, and van der Graaf WTA, Te insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895-1904. (Pubitemid 47284866)
8. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, and Macaulay VM, Te type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008;14(20):6364-6370.
9. Paz K, Hadari YR. Targeted therapy of the insulin-like growth factor-1 receptor in cancer. Comb Chem High Troughput Screen 2008;11:62-69.
10. Miller B, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005;65(22): 10123-10127. (Pubitemid 41743697)
11. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, and Macaulay VM, Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ter 2005;12:90-100. (Pubitemid 39665247)
12. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol 2008;13: 471-483.
13. Párrizas M, Gazit A, Levitzki A, Wertheimer E, and Le roith D, Specifc inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and bilogical function by tyr-phostins. Endocrinology 1997;138(4):1427-1433. (Pubitemid 27137089)
14. Deutsch E, Maggiorella L, Wen B, Bonnet ML, Khanfr K, Frascogna V, Turhan AG, and Bourhis J, Tyrosine kinase inhibitor AG1024 exerts antileukaemic efects on ST1571-resistant Bcr-Abl expressing cells and decrease AKT phosphorylation. Br J Cancer 2004;91:1735-1741. (Pubitemid 39546148)
15. Wen B, Deutsch E, Frascona V, Maggiorella L, Abdulkarim B, Chavaudra N, and Bourhis J, Tyrphostin AG 1024 modulates radiosencitivity in human breast cancer cells. Br J Cancer 2001;85(12):2017-2021. (Pubitemid 34775342)
16. Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V, Alexandru O, Banita M, Pisoschi C, Bäcklund ML, Lewensohn R, and Dricu A, Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. J Neuro-Oncol 2007;85:245-254. (Pubitemid 350142513)
17. Benini S, Manara MC, Baldini N, Cerisano V, Serra M, Mercuri M, Lollini PL, Nanni P, Picci P, and Scotlandi K, Inhibition of insulinlike growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7:1790-1797. (Pubitemid 32708650)
18. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, and de Alava E, Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with lmatinib, doxorubicin or vincristine is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12(11):3532- 3540.
19. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, and Greenfeld EM, Specifc tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res 2008;466:2168-2175.
20. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, de Giovanni C, Tofoli G, and Baldini N, Establishment and characterization of multidrug-resistant human osteosarcoma cell lines. An-ticancer Res 1993;13:323-330.
21. Hattinger CM, Stoico G, Michelacci F, Pasello M, Scionti I, Re-mondini D, Castellani GC, Fanelli M, Scotlandi K, Picci P, and Serra M, Mechanisms of gene amplifcation and evidence of coam-plifcation in drug-resistant human osteosarcoma cell lines. Genes Chromosome Cancer 2009;48:289-309.
22. Rasband WS. Image J. Bethesda, MD: US National Institute of Health, 1997-2008. http://rsb.info.nih.gov/ij/.
23. Chou TC, Talalay P. Quantitative analysis of does-efect relationship: the combined efects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
24. Niyazi M, Niyazi I, Belka C. Counting colonies of clonogenic assays by using densitometric sofware. Radiat Oncol 2007;2:4.
25. Franken NAP, Rodermond HM, Stap J, Haveman J, and van Bree C, Clonogenic assay of cells in vitro. Nat Protoc 2006;1(5):2315-2319.
26. Bahr C, Groner B. Te IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005;23(1):1-14. (Pubitemid 41656866)
27. Baserga R, Peruzzi F, Reiss K. Mini-Review: the IGF-1 receptor in cancer biology. Int J Cancer 2003;107:873-877. (Pubitemid 37429826)
28. von Willebrand M, Zacksenhaus E, Chen E, Glazer P, and Halaban R, Te Tyrphostin AG1024 accelerates the degradation of phos-phorylated forms of retinoblastoma protein (pRb) and restores pRb tumor suppressive function in melanoma cells. Cancer Res 2003;63:1420-1429. (Pubitemid 36348726)
29. Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I recptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001;8:325-329. (Pubitemid 33758087)
30. Kai K, D'Costa S, Sills RC, and Kim Y, Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor efect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009;278:49-55.
31. Burrow S, Andrulis IL, Pollak M, and Bell RS, Expression of insulin-like growth factor receptor, IGF-1 and IGF-2 in primary and metastatic osteosarcoma. Eur J Surg Oncol 1998;69:21-27. (Pubitemid 28452269)
32. Dunn SE, Hardman RA, Kari FW, and Barrett JC, Insulin-like growth factor 1 (IGF-1R) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-2693. (Pubitemid 27283781)
33. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004;108:334-341. (Pubitemid 37549597)
34. Yu D, Watanabe H, Shibuya H, and Miura M, Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem 2003;278:6702-6709. (Pubitemid 36800657)
35. Carrle D, Bielack SS. Current strategies of chemotherapy in os-teosarcoma. Int Orthop 2006;30(6):445-451.
36. Wittig JC, Bickles J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, and Malawer MM, Osteosarcoma: a multidisci-plinary approach to diagnosis and treatment. Am Fam Physician 2002;65(6):1123-1132.
37. Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 2008;8:384-392.
38. Lindsay CR, Chan E, Evans TR, Campbell S, Bell P, Stephens AW, Franke A, Poondru S, Rothenberg ML, and Puzanov I, Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors (2009 ASCO Annual Meeting Proceedings Post-Meeting Edition). J Clin Oncol 2009;27(15S):2559.
39. Rosenthal SM, Cheng ZQ. Opposing early and late efects of insulin-like growth factor I on diferentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc Nat Acad Sci USA 1995;92:10307-10311.
40. Dupont J, Karas M, Le Roith D. Te potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes ceel cycle components. J Biol Chem 2000;275:35893-35901.
41. Coats S, Flanagan WM, Nourse J, and Roberts JM, Requirement of p27Kip1 for restriction point control of the fbroblast cell cycle. Science 1996;272:877-880.
42. Samani AA, Yakar S, Le roith D, and Brodt P, Te role of the IGF system in cancer growth and metasis: overview an recent insights. Endocr Rev 2007;28(1):20-47. (Pubitemid 46220849)
43. Tyagi AK, Singh RP, Agarwal C, Chan DCF, and Agarwal R, Silib-inin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apop-tosis. Clin Cancer Res 2002;8:3512-3519. (Pubitemid 35340729)
44. DiPaola RS. To arrest or not to G2-M cell-cycle arrest. Clin Cancer Res 2002;8:3311-3314.
45. Kisielewska J, Ligeza J, Klein A. Te efect of tyrosine ki-nase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growthof prostate cancer cells (DU145). Folia Histochem Cyto 2008;46(2):185-191.
46. Timofeev O, Cizmecioglu O, Settele F, Kempf T, and Hof-mann I, Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem 2010;285(22):16978-16990.
47. Hu B, Mitra J, van den Heuvel S, and Enders GH, S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001;21(8):2755-2766. (Pubitemid 32244920)
48. Welch PJ, Wang JY. Coordinated synthesis and degradation of cdc2 in the mammalian cell cycle. Proc Nat Acad Sci USA 1992;89(7):3093-3097.
49. Rajkumar T, Yamuna M. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line. Anti-Cancer Drugs 2008;19:257-265.
50. Yuan X, Zhu X, Huang X, Sheng P, He A, Yang Z, Deng R, Feng G, and Liao W, Interferon-a enhances sensitivity of human os-teosarcoma U2-OS cells to doxorubicin by p53-dependent apop-tosis. Acta Pharm Sin 2007;28(11):1835-1841. doi:10.1111/j.1745-7254.2007.00662.x. (Pubitemid 350029330)
51. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, and Friend SH, p53 functions as a cell cycle control protein in osetosarcomas. Mol Cell Biol 1990;10(11):5772-5781.
52. Lock RB, Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without afection clonogenic survival. Cancer Res 1996;56:4006-4012. (Pubitemid 26284752)
53. Deplanque G, Ceraline J, Lapouge G, Dufour P, Bergerat JP, and Klein-Soyer C, Conficting efects of cafeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with diferent p53 status afer exposure to cisplatin or UVc irradiation. Biochem Bioph Res Commun 2004;314:1100-1106. (Pubitemid 38142396)
54. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-1399. (Pubitemid 29160097)
55. Gokgoz N, Wunder JS, Mousses S, Eskandarian S, Bell RS, and Andrulis IL, Comparison of p53 mutation in patients with localized osteosarcoma and metastatic osteosarcom. Cell 2001;92:2181-2189. (Pubitemid 32973330)
56. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlock R, and Levine AJ, Te presence of p53 mutations in human osteosarcomas correlates with high levels of ge-nomic instability. Proc Nat Acad Sci USA 2003;100:11547-11552. (Pubitemid 37205973)